Publications by authors named "Mark Ozeck"

Claim this Profile
I
Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
Wen Yan, Chi-Yeh Chung, Tao Xie, Mark Ozeck, Timothy C Nichols

Mol Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Jeffrey W Clark, D Ross Camidge, Eunice L Kwak, Robert G Maki, Geoffrey I Shapiro, Mark Ozeck

Future Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.
John J Arcaroli, W M Tai, Ryan McWilliams, Stacey Bagby, Patrick J Blatchford, Mark Ozeck

Int J Cancer· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Kai Wang, Qin Zhang, Danan Li, Keith Ching, Cathy Zhang, Mark Ozeck

Clin Cancer Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Maruja E Lira, Yoon-La Choi, Sun Min Lim, Shibing Deng, Donghui Huang, Mark Ozeck

J Mol Diagn· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Douglas D Fang, Bin Zhang, Qingyang Gu, Maruja Lira, Qiang Xu, Mark Ozeck

J Thorac Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).
Adam Pavlicek, Maruja E Lira, Nathan V Lee, Keith A Ching, Jingjing Ye, Mark Ozeck

Mol Cancer Ther· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
Cathy C Zhang, Adam Pavlicek, Qin Zhang, Maruja E Lira, Cory L Painter, Mark Ozeck

Clin Cancer Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
Kenneth E Hook, Scott J Garza, Maruja E Lira, Keith A Ching, Nathan V Lee, Mark Ozeck

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways.
Mark Ozeck, Paul Brust, Hong Xu, Guy Servant

Eur J Pharmacol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Affinity and intrinsic efficacy (IE) of 5'-carbamoyl adenosine analogues for the A1 adenosine receptor--efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF).
Venkata P Palle, Vaibhav Varkhedkar, Prabha Ibrahim, Hiba Ahmed, Zhihe Li, Mark Ozeck

Bioorg Med Chem Lett· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside, an A1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats.
Heather Fraser, Zhenhai Gao, Mark J Ozeck, Luiz Belardinelli

J Pharmacol Exp Ther· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tonic activity of the rat adipocyte A1-adenosine receptor.
Hui-Xiu Liang, Luiz Belardinelli, Mark J Ozeck, John C Shryock

Br J Pharmacol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis